Advanced Enzyme Technologies Approves FY26 Results, Recommends ₹1.35 Dividend; Updates Governance
Advanced Enzyme Technologies Limited (AET) approved its Annual Financial Results (Standalone and Consolidated) for the financial year ended March 31, 2026, at a Board Meeting held on May 9, 2026. The Board recommended a Final Dividend of ₹ 1.35 per Equity Share, representing a 67.5% return on the face value of ₹ 2 per share for the fiscal year 2025-26, subject to shareholder approval at the forthcoming Annual General Meeting (AGM).The Board also decided to defer the declaration of an interim dividend, citing an intent to preserve capital to provide flexibility for evaluating potential strategic avenues that could maximize long-term shareholder value.
Corporate Governance Appointments and Reappointments
The Board conducted several key appointments and reappointments:- Whole-Time Director: Mr. Mukund Madhusudan Kabra was approved for re-appointment as Whole-Time Director for another term of five years, effective from April 01, 2027, to March 31, 2032.
- Additional Director: Mr. Pradip Bhailal Shah was approved for appointment as an Additional Director (Independent), effective June 12, 2026, for a term of five years, ending on June 11, 2031.
- Statutory Auditors: M S K A & Associates LLP, Chartered Accountants, was approved for reappointment as the Statutory Auditors for a second term of five consecutive years, spanning from the conclusion of the 37th AGM until the conclusion of the 42nd AGM.
Financial Structure Updates
The company also recorded an increase in its share capital following the allotment of 49,350 Equity Shares. These shares were allotted via the Exercise of Options under the Employee Stock Options Scheme 2022. Consequent to this allotment, the paid-up share capital of the Company increased from ₹ 22,38,53,600 to ₹ 22,39,52,300.Financial Performance Snapshot
The company presented detailed audited financial results for the year ended March 31, 2026.The comprehensive financial results are available for review:
Consolidated Financial Results Highlights (₹ in million)
| Metric | Year ended 31 March 2026 | Year ended 31 March 2025 |
|---|---|---|
| Total Income (1+2) | 7,805.89 | 6,699.51 |
| Total Expenses | 5,594.12 | 4,825.87 |
| Profit before tax | 2,325.36 | 1,873.64 |
| Net profit for the period | 1,736.08 | 1,339.74 |
| Comprehensive income attributable to Shareholders | 2,634.61 | 1,499.41 |
| Earnings Per Share (Basic) | 3.84 | 2.85 |
Standalone Financial Results Highlights (₹ in million)
| Metric | Year ended 31 March 2026 | Year ended 31 March 2025 |
|---|---|---|
| Total Income (1+2) | 5,161.54 | 4,129.01 |
| Total Expenses | 3,546.22 | 2,923.73 |
| Profit before tax | 1,576.74 | 1,205.28 |
| Net profit for the period | 1,318.06 | 1,024.20 |
| Earnings Per Share (Basic) | 11.78 | 9.16 |
Balance Sheet Position
The company's balance sheet shows steady growth in assets and equity.Consolidated Balance Sheet (₹ in million)
| Particulars | As at 31 March 2026 | As at 31 March 2025 |
|---|---|---|
| Total Assets | 18,387.61 | 16,213.47 |
| Total Equity | 16,831.22 | 14,686.70 |
Standalone Balance Sheet (₹ in million)
| Particulars | As at 31 March 2026 | As at 31 March 2025 |
|---|---|---|
| Total Assets | 8,036.36 | 6,886.31 |
| Total Equity | 7,096.23 | 6,293.41 |
Cash Flow Summary
The cash flow statement details operating, investing, and financing activities.Consolidated Cash Flow Statement (₹ in million)
| Activity | Year ended 31 March 2026 | Year ended 31 March 2025 |
|---|---|---|
| Cash generated from operating activities | 2,219.03 | 2,021.71 |
| Net cash used in investing activities | (741.30) | (891.01) |
| Net cash used in financing activities | (703.66) | (725.44) |
| Net cash and cash equivalents increase / (decrease) | 122.80 | (191.48) |
For a detailed review of the full financial results, including operational statements and cash flow analyses, Advanced Enzyme Technologies Limited provides comprehensive statements for both consolidated and standalone financials.
ADVENZYMES Stock Price Movement
On Friday, Advanced Enzyme Technologies Limited shares gained 0.53% to settle at ₹357.25. The stock recorded substantial momentum on 421,044 shares traded, reaching an impressive 52-week high of ₹372.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.